About this document
Oral SERDs for HR+ HER2- Breast Cancer by descalera351 is a document available to read on EtoBox.
This review discusses the role of oral selective estrogen receptor degraders (SERDs) in treating hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitors, particularly focusing on their efficacy against ESR1 mutations. Key clinical trials demonstrate that oral SERDs improve bioavailability and convenience compared to traditional therapies, addressing resistance mechanisms and potentially enhancing patient outcomes. The review emphasizes the need for further t
- Author
- descalera351
- Language
- EN